Research programme: tumour maintenance gene antagonists - AVEO/Merck

Drug Profile

Research programme: tumour maintenance gene antagonists - AVEO/Merck

Latest Information Update: 13 Aug 2007

Price : $50

At a glance

  • Originator AVEO Pharmaceuticals; Merck & Co
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Aug 2007 AVEON Pharmaceuticals has successfully completed its multi-year collaborative agreement with Merck & Co
  • 03 Mar 2005 GenPath Pharmaceuticals is now called AVEO Pharmaceuticals
  • 17 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top